Table 1 Relationship between TRIM22 expression level and clinicopathologic variables in 90 gastric cancer tissues.
From: TRIM22 inhibits the proliferation of gastric cancer cells through the Smad2 protein
Clinicopathologic parameters | TRIM22 protein | P | |
|---|---|---|---|
− | + | ||
(n = 63) | (n = 27) | ||
Age (years) | |||
≤60 | 25 | 9 | 0.569 |
>60 | 38 | 18 | Â |
Gender | |||
Male | 36 | 20 | 0.129 |
Female | 27 | 7 | Â |
Tumor size (cm) | |||
≤5 | 40 | 23 | 0.04 |
>5 | 23 | 4 | Â |
Lauren classification | |||
Intestinal | 27 | 15 | 0.268 |
Diffuse | 36 | 12 | Â |
Differentiation | |||
Well, moderately | 25 | 11 | 0.925 |
Poorly, undifferentiated | 38 | 16 | Â |
Local invasion | |||
T1, T2 | 14 | 19 | <0.01 |
T3, T4 | 49 | 8 | Â |
Lymph node metastasis | |||
No | 11 | 5 | 0.904 |
Yes | 52 | 22 | Â |
TNM stage | |||
I, II | 24 | 14 | 0.226 |
III, IV | 39 | 13 | Â |
